The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Ruxolitinib in pediatric patients with chronic GvHD: Interim results from REACH5
|
The ongoing phase II REACH5 trial (NCT03774082) is assessing the safety and efficacy of ruxolitinib plus corticosteroids for the treatment of corticosteroid-refractory or treatment-naïve pediatric patients with moderate-to-severe chronic graft-versus-host disease (GvHD).1 The study design has previously been reported by the GvHD Hub. Interim results from this trial, including the final evaluation of the primary endpoint, were published in Lancet Haematology by Locatelli, et al.1 |
| Key learnings: |
|
The overall response rates at Cycle 7 Day 1 (primary endpoint) were 40.0%, 41.2%, and 39.3% in all patients, treatment-naïve patients, and corticosteroid-refractory patients, respectively. |
|
The safety profile of ruxolitinib in pediatric patients was consistent with the known safety profile in adult and adolescent patients, with the most common treatment-related adverse events (TRAEs) being neutropenia (24%), thrombocytopenia (18%), and anemia (16%).
|
|
Median overall survival and failure-free survival were not reached, and at 12-months the estimated probability of survival and failure-free survival were 84.2% and 66.7%, respectively. |
|
These findings demonstrate the tolerable safety profile and high response rates of ruxolitinib plus corticosteroids in treatment-naïve and corticosteroid-refractory patients aged 2–18 years with chronic GvHD. The final analysis of this trial will provide further data on the long-term safety and efficacy of ruxolitinib in this patient population. |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
